Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 361.56M | 336.21M | 251.03M | 200.81M | 103.93M |
Gross Profit | 251.21M | 229.93M | 162.13M | 118.70M | 45.38M |
EBITDA | -113.32M | -386.05M | -347.91M | -126.43M | -227.43M |
Net Income | -49.45M | -471.53M | -454.39M | -183.26M | -608.98M |
Balance Sheet | |||||
Total Assets | 2.68B | 2.58B | 3.00B | 3.36B | 1.11B |
Cash, Cash Equivalents and Short-Term Investments | 1.36B | 1.07B | 1.87B | 2.21B | 612.47M |
Total Debt | 76.86M | 70.48M | 95.47M | 125.64M | 15.83M |
Total Liabilities | 454.07M | 242.25M | 247.55M | 265.52M | 1.46B |
Stockholders Equity | 2.19B | 2.33B | 2.75B | 3.10B | -345.18M |
Cash Flow | |||||
Free Cash Flow | -270.06M | -237.50M | -231.60M | -269.94M | -167.97M |
Operating Cash Flow | -111.67M | -206.99M | -182.53M | -161.50M | -109.75M |
Investing Cash Flow | -798.50M | -596.06M | -179.78M | -437.48M | -56.42M |
Financing Cash Flow | -56.31M | -25.61M | -136.42M | 2.23B | 676.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
47 Neutral | HK$2.22B | ― | -2.19% | ― | 5.32% | 89.43% | |
46 Neutral | C$194.28M | -4.22 | -8.60% | 2.64% | 13.54% | -1.44% | |
€500.81M | ― | -10.43% | ― | ― | ― | ||
75 Outperform | HK$6.78B | 22.73 | 10.92% | 1.19% | 20.19% | 45.54% | |
65 Neutral | HK$7.09B | 35.93 | 4.39% | 0.82% | -32.05% | -54.47% | |
50 Neutral | HK$1.13B | ― | -27.82% | ― | -6.12% | 0.43% | |
47 Neutral | HK$286.54M | 0.29 | 1417.08% | ― | -20.01% | ― |
MicroPort CardioFlow Medtech Corp. announced the results of its Annual General Meeting held on June 27, 2025, where all proposed resolutions were approved by shareholders. The meeting also marked the retirement of an independent non-executive director and the appointment of a new one, leading to changes in the composition of the board committees. These developments are expected to influence the company’s governance and strategic direction, potentially impacting its market position and stakeholder relationships.
MicroPort CardioFlow Medtech Corp. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement is significant for stakeholders as it outlines the leadership structure, which can influence the company’s strategic direction and governance.
MicroPort CardioFlow Medtech Corporation has announced its upcoming Annual General Meeting scheduled for June 27, 2025, in Shanghai, China. The meeting will address several key resolutions, including the approval for the directors to repurchase shares and to issue additional shares or securities. These resolutions, if passed, could impact the company’s capital structure and shareholder value, reflecting strategic moves to enhance market positioning and operational flexibility.
MicroPort CardioFlow Medtech Corp. has announced its acquisition of the remaining 49% equity interest in MP CardioAdvent, making it a wholly-owned subsidiary. This move is part of a strategic effort to consolidate its holdings and strengthen its position in the cardiovascular device market. The acquisition is classified as a disclosable and connected transaction under Hong Kong’s Listing Rules, requiring approval from independent shareholders.